Researchers in Japan have developed a CRISPR-Cas-based system to edit epigenetic marks in mouse sperm, enabling direct investigation of whether DNA...
nChroma Bio has received regulatory clearance in Hong Kong to initiate a Phase 1/2 clinical trial of its lead candidate CRMA-1001, marking the first...
American researchers have developed an RNA-based platform that uses CRISPR epigenetic editors to durably silence or activate genes in primary human T...
Researchers have developed a compact, all-in-one CRISPR-dCas9-based repressor platform delivered via AAV, effectively silencing gene expression...
Korean researchers have developed programmable conditional guide RNAs for precise control of endogenous gene expression using the CRISPR-Cas system....
In a recent study, researchers in Italy addressed the critical need for experimental validation of durable epigenetic silencing after transient...
Leading epigeneticist Gabriella Ficz has used CRISPR technology to investigate the interplay between DNA methylation and cancer. Her latest findings...
CRISPR-Cas is seen as the holy grail in medicine for rare and incurable genetic diseases. In this piece, we take a look at what CRISPR can do for...
